{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:03:28Z","timestamp":1785506608750,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s41669-025-00577-z","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T15:47:30Z","timestamp":1745336850000},"page":"541-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed\/Refractory Follicular Lymphoma"],"prefix":"10.1007","volume":"9","author":[{"given":"Bijal","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Furnback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlene K.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ya","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Dec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"577_CR1","unstructured":"Lymphoma Research Foundation, Follicular lymphoma. 2023. https:\/\/lymphoma.org\/wp-content\/uploads\/2023\/10\/LRF_Understanding_Lymphoma_Follicular_Lymphoma_Fact_Sheet.pdf. Accessed 11 July 2024."},{"issue":"2","key":"577_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/ejh.12403","volume":"94","author":"M Mounier","year":"2015","unstructured":"Mounier M, et al. Trends in excess mortality in follicular lymphoma at a population level. Eur J Haematol. 2015;94(2):120\u20139. https:\/\/doi.org\/10.1111\/ejh.12403.","journal-title":"Eur J Haematol"},{"issue":"1","key":"577_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000317","volume":"4","author":"K H\u00fcbel","year":"2020","unstructured":"H\u00fcbel K, et al. Controversies in the treatment of follicular lymphoma. Hemasphere. 2020;4(1): e317. https:\/\/doi.org\/10.1097\/HS9.0000000000000317.","journal-title":"Hemasphere"},{"issue":"3","key":"577_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15(3):1110\u20137.","journal-title":"J Clin Oncol"},{"key":"577_CR5","unstructured":"Singh D, Singh A, Mukkamalla SKR. Relapsed and refractory follicular lymphoma. In: StatPearls [Internet]. StatPearls Publishing; 2023."},{"issue":"7","key":"577_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74. https:\/\/doi.org\/10.1038\/s41408-020-00340-z.","journal-title":"Blood Cancer J"},{"issue":"4","key":"577_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.15149","volume":"184","author":"BK Link","year":"2019","unstructured":"Link BK, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019;184(4):660\u20133. https:\/\/doi.org\/10.1111\/bjh.15149.","journal-title":"Br J Haematol"},{"issue":"1","key":"577_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00277-018-3501-8","volume":"98","author":"N Monga","year":"2019","unstructured":"Monga N, et al. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019;98(1):175\u201383. https:\/\/doi.org\/10.1007\/s00277-018-3501-8.","journal-title":"Ann Hematol"},{"issue":"3","key":"577_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/annonc\/mdm543","volume":"19","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol. 2008;19(3):570\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdm543.","journal-title":"Ann Oncol"},{"key":"577_CR10","unstructured":"National Comprehensive Cancer Network, Guideline of B-cell lymphomas (Version 1.2024). 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed 29 Jan 2024."},{"key":"577_CR11","unstructured":"U.S. Food and Drug Administration. FDA D.I.S.C.O. Burst Edition: FDA approval of Lunsumio (mosunetuzumab-axgb) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. 2022."},{"key":"577_CR12","unstructured":"U.S. Food and Drug Administration. FDA approves tisagenlecleucel for relapsed or refractory follicular lymphoma. 2022."},{"key":"577_CR13","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma. 2021."},{"key":"577_CR14","unstructured":"U.S. Food and Drug Administration. FDA granted accelerated approval to tazemetostat for follicular lymphoma. 2020."},{"key":"577_CR15","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma. 2024."},{"issue":"11","key":"577_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(20)30441-1.","journal-title":"Lancet Oncol"},{"issue":"8","key":"577_CR17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(22)00335-7.","journal-title":"Lancet Oncol"},{"issue":"1","key":"577_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91\u2013103. https:\/\/doi.org\/10.1016\/S1470-2045(21)00591-X.","journal-title":"Lancet Oncol"},{"issue":"2","key":"577_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0.","journal-title":"Nat Med"},{"key":"577_CR20","unstructured":"Wells GA, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"577_CR21","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"issue":"4","key":"577_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.18553\/jmcp.2019.18259","volume":"25","author":"S Appukkuttan","year":"2019","unstructured":"Appukkuttan S, et al. A budget impact analysis of the introduction of copanlisib for treatment of relapsed follicular lymphoma in the United States. J Manag Care Spec Pharm. 2019;25(4):437\u201346. https:\/\/doi.org\/10.18553\/jmcp.2019.18259.","journal-title":"J Manag Care Spec Pharm"},{"key":"577_CR23","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1182\/blood-2023-181854","volume":"142","author":"S Bains Chawla","year":"2023","unstructured":"Bains Chawla S, et al. Patterns of care and resource use among elderly relapsed\/refractory follicular lymphoma patients: US Medicare claims analysis. Blood. 2023;142:5158. https:\/\/doi.org\/10.1182\/blood-2023-181854.","journal-title":"Blood"},{"issue":"10 a","key":"577_CR24","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.18553\/jmcp.2023.29.10-a.s1","volume":"29","author":"P Chan","year":"2023","unstructured":"Chan P, et al. Real-world use of chimeric antigen receptor T-cell therapy vs standard of care for relapsed\/refractory follicular lymphoma at third-line treatment or higher: analysis of treatment patterns, health care resource utilization, and costs in the United States. J Manag Care Spec Pharm. 2023;29(10 a):S32. https:\/\/doi.org\/10.18553\/jmcp.2023.29.10-a.s1.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"577_CR25","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1016\/j.jval.2023.09.931","volume":"26","author":"L Chen","year":"2023","unstructured":"Chen L, et al. EE666 cost-effectiveness of duvelisib versus the bendamustine plus rituximab regimen for relapsed\/refractory follicular lymphoma patients in China. Value Health. 2023;26(12):S181\u20132. https:\/\/doi.org\/10.1016\/j.jval.2023.09.931.","journal-title":"Value Health"},{"issue":"Supplement 1","key":"577_CR26","doi-asserted-by":"publisher","first-page":"10818","DOI":"10.1182\/blood-2022-164915","volume":"140","author":"M Di","year":"2022","unstructured":"Di M, et al. Total costs of care during chimeric antigen receptor t-cell therapy in patients with relapsed\/refractory B cell non-hodgkin lymphoma: a large private insurance claim-based analysis. Blood. 2022;140(Supplement 1):10818\u20139. https:\/\/doi.org\/10.1182\/blood-2022-164915.","journal-title":"Blood"},{"issue":"12","key":"577_CR27","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1016\/j.jval.2023.09.801","volume":"26","author":"O Eklund","year":"2023","unstructured":"Eklund O, et al. EE536 cost-effectiveness of axicabtagene ciloleucel (axi-cel) vs standard of care for adult patients with relapsed or refractory follicular lymphoma as 4th or later line treatment in sweden. Value Health. 2023;26(12):S155.","journal-title":"Value Health"},{"key":"577_CR28","doi-asserted-by":"publisher","first-page":"S481","DOI":"10.1016\/j.jval.2019.09.428","volume":"22","author":"E Erdogan-Ciftci","year":"2019","unstructured":"Erdogan-Ciftci E, et al. PCN233 cost effectiveness of obinutuzumab plus bendamustine vs bendamustine alone for patients who did not respond or progressed during or after rituximab or a rituximab containing regiment in Turkey. Value Health. 2019;22:S481.","journal-title":"Value Health"},{"key":"577_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174403","author":"AJM Ferreri","year":"2023","unstructured":"Ferreri AJM, et al. Burden of illness in follicular lymphoma with multiple lines of treatment, Italian RWE analysis. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15174403.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"577_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.36469\/jheor.2020.16784","volume":"7","author":"NH Fowler","year":"2020","unstructured":"Fowler NH, et al. Treatment patterns and health care costs in commercially insured patients with follicular lymphoma. J Health Econ Outcomes Res. 2020;7(2):148\u201357. https:\/\/doi.org\/10.36469\/jheor.2020.16784.","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"577_CR31","doi-asserted-by":"publisher","first-page":"60.e1","DOI":"10.1016\/j.jtct.2022.09.022","volume":"29","author":"NH Fowler","year":"2023","unstructured":"Fowler NH, et al. Assessment of healthcare resource utilization and hospitalization costs in patients with relapsed or refractory follicular lymphoma undergoing CAR-T cell therapy with tisagenlecleucel: results from the ELARA study. Transplant Cell Ther. 2023;29(1):60.e1-60.e4. https:\/\/doi.org\/10.1016\/j.jtct.2022.09.022.","journal-title":"Transplant Cell Ther"},{"issue":"15_suppl","key":"577_CR32","doi-asserted-by":"publisher","first-page":"e18836","DOI":"10.1200\/JCO.2021.39.15_suppl.e18836","volume":"39","author":"S Gaballa","year":"2021","unstructured":"Gaballa S, et al. Health care cost impact associated with adverse events (AEs) among treatments in third-line+ (3L+) relapsed\/refractory follicular lymphoma (R\/R FL). J Clin Oncol. 2021;39(15_suppl):e18836. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e18836.","journal-title":"J Clin Oncol"},{"issue":"5","key":"577_CR33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s10637-023-01389-w","volume":"41","author":"B Ghanem","year":"2023","unstructured":"Ghanem B. Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma. Investig New Drugs. 2023;41(5):710\u20138. https:\/\/doi.org\/10.1007\/s10637-023-01389-w.","journal-title":"Investig New Drugs"},{"issue":"4-A SUPPL","key":"577_CR34","first-page":"S48","volume":"27","author":"S Jeyakumar","year":"2021","unstructured":"Jeyakumar S, et al. Umbralisib improves tolerability and associated cost burden of adverse events over pi3k inhibitors in relapsed\/refractory (R\/R) follicular lymphoma (FL) patients: results from matching-adjusted indirect comparison. J Manag Care Spec Pharm. 2021;27(4-A SUPPL):S48.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"577_CR35","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.3390\/curroncol30050352","volume":"30","author":"J Kuruvilla","year":"2023","unstructured":"Kuruvilla J, et al. Estimating the burden of illness of relapsed follicular lymphoma and marginal zone lymphoma in Ontario, Canada. Curr Oncol. 2023;30(5):4663\u201376. https:\/\/doi.org\/10.3390\/curroncol30050352.","journal-title":"Curr Oncol"},{"issue":"3","key":"577_CR36","first-page":"75","volume":"15","author":"L Leslie","year":"2022","unstructured":"Leslie L, et al. Real-world treatment patterns and healthcare costs among patients with FL with early treatment failure of first-line chemoimmunotherapy. Am Health Drug Benefits. 2022;15(3):75\u201385.","journal-title":"Am Health Drug Benefits"},{"issue":"Supplement 1","key":"577_CR37","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood-2023-182244","volume":"142","author":"M Lin","year":"2023","unstructured":"Lin M, et al. Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed\/refractory follicular lymphoma. Blood. 2023;142(Supplement 1):256\u2013256. https:\/\/doi.org\/10.1182\/blood-2023-182244.","journal-title":"Blood"},{"issue":"6","key":"577_CR38","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.jval.2023.03.453","volume":"26","author":"SW Lin","year":"2023","unstructured":"Lin SW, et al. EE150 A budget impact analysis of the introduction of mosunetuzumab for treatment of third- or higher-line (3l+) relapsed or refractory (r\/r) follicular lymphoma (fl) in the United States (US). Value Health. 2023;26(6):S87.","journal-title":"Value Health"},{"issue":"12","key":"577_CR39","doi-asserted-by":"publisher","first-page":"e230073","DOI":"10.57264\/cer-2023-0073","volume":"12","author":"J Ma","year":"2023","unstructured":"Ma J, et al. Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma. J Comp Eff Res. 2023;12(12):e230073. https:\/\/doi.org\/10.57264\/cer-2023-0073.","journal-title":"J Comp Eff Res"},{"issue":"6","key":"577_CR40","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1016\/j.jval.2023.03.2493","volume":"26","author":"M Matasar","year":"2023","unstructured":"Matasar M, et al. EE514 A cost-effectiveness analysis of mosunetuzumab for treatment of third-or higher-line relapsed or refractory (r\/r) follicular lymphoma (fl) in the United States (US). Value Health. 2023;26(6):S153.","journal-title":"Value Health"},{"issue":"Supplement 1","key":"577_CR41","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2021-145407","volume":"138","author":"MJ Matasar","year":"2021","unstructured":"Matasar MJ, et al. Healthcare resource utilization and costs of patients with relapsed\/refractory follicular lymphoma receiving 3 or more lines of therapy. Blood. 2021;138(Supplement 1):1923\u20131923. https:\/\/doi.org\/10.1182\/blood-2021-145407.","journal-title":"Blood"},{"issue":"Supplement 1","key":"577_CR42","doi-asserted-by":"publisher","first-page":"10822","DOI":"10.1182\/blood-2022-163789","volume":"140","author":"OO Oluwole","year":"2022","unstructured":"Oluwole OO, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States. Blood. 2022;140(Supplement 1):10822\u20134. https:\/\/doi.org\/10.1182\/blood-2022-163789.","journal-title":"Blood"},{"issue":"Supplement 1","key":"577_CR43","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1182\/blood-2023-186548","volume":"142","author":"OO Oluwole","year":"2023","unstructured":"Oluwole OO, et al. Cost-effectiveness of axicabtagene ciloleucel versus mosunetuzumab in relapsed\/refractory follicular lymphoma in the US. Blood. 2023;142(Supplement 1):5082\u20135082. https:\/\/doi.org\/10.1182\/blood-2023-186548.","journal-title":"Blood"},{"issue":"5","key":"577_CR44","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","volume":"7","author":"KC Potnis","year":"2023","unstructured":"Potnis KC, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv. 2023;7(5):801\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2022008097.","journal-title":"Blood Adv"},{"issue":"4-A SUPPL","key":"577_CR45","first-page":"S40","volume":"27","author":"D Proudman","year":"2021","unstructured":"Proudman D, et al. Budget impact analysis of tazemetostat for third-line or later (3l+) relapsed or refractory follicular lymphoma. J Manag Care Spec Pharm. 2021;27(4-A SUPPL):S40\u20131.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10 a","key":"577_CR46","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.18553\/jmcp.2023.29.10-a.s1","volume":"29","author":"A Saunders","year":"2023","unstructured":"Saunders A, et al. Treatment patterns, health care resource utilization, and cost among commercially insured patients with relapsed\/refractory follicular lymphoma in the United States: MarketScan 2015\u20132021. J Manag Care Spec Pharm. 2023;29(10 a):S30. https:\/\/doi.org\/10.18553\/jmcp.2023.29.10-a.s1.","journal-title":"J Manag Care Spec Pharm"},{"issue":"Supplement 1","key":"577_CR47","doi-asserted-by":"publisher","first-page":"7247","DOI":"10.1182\/blood-2023-178776","volume":"142","author":"AC Saunders","year":"2023","unstructured":"Saunders AC, Badaracco J. An economic model to estimate costs of cytokine release syndrome and neurological events among patients treated with CAR T cell therapies for relapsed or refractory follicular lymphoma. Blood. 2023;142(Supplement 1):7247\u20137247. https:\/\/doi.org\/10.1182\/blood-2023-178776.","journal-title":"Blood"},{"issue":"Supplement 1","key":"577_CR48","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1182\/blood-2023-178771","volume":"142","author":"AC Saunders","year":"2023","unstructured":"Saunders AC, et al. Health care resource utilization (HCRU) and cost of management of cytokine release syndrome (CRS) and neurological events (NEs) in patients with R\/R follicular lymphoma (FL) receiving lisocabtagene maraleucel (liso-cel) in the TRANSCEND FL study. Blood. 2023;142(Supplement 1):7257\u20137257. https:\/\/doi.org\/10.1182\/blood-2023-178771.","journal-title":"Blood"},{"issue":"Supplement 1","key":"577_CR49","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1182\/blood-2023-179556","volume":"142","author":"BD Shah","year":"2023","unstructured":"Shah BD, et al. Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States. Blood. 2023;142(Supplement 1):5137\u20135137. https:\/\/doi.org\/10.1182\/blood-2023-179556.","journal-title":"Blood"},{"issue":"12","key":"577_CR50","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1080\/14737140.2021.1971520","volume":"21","author":"FW Thielen","year":"2021","unstructured":"Thielen FW, et al. Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. Expert Rev Anticancer Ther. 2021;21(12):1411\u201322. https:\/\/doi.org\/10.1080\/14737140.2021.1971520.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"577_CR51","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1038\/s41409-021-01327-5","volume":"56","author":"A Vijenthira","year":"2021","unstructured":"Vijenthira A, Kuruvilla J, Prica A. Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy. Bone Marrow Transplant. 2021;56(10):2400\u20139. https:\/\/doi.org\/10.1038\/s41409-021-01327-5.","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"577_CR52","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood-2023-182244","volume":"142","author":"M Lin","year":"2023","unstructured":"Lin M, et al. Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed\/refractory follicular lymphoma. Blood. 2023;142(Supplement 1):256\u2013256.","journal-title":"Blood"},{"key":"577_CR53","doi-asserted-by":"publisher","first-page":"S391","DOI":"10.1016\/S2152-2650(22)01563-4","volume":"22","author":"C Chang","year":"2022","unstructured":"Chang C, et al. IBCL-425 disease burden and treatment patterns of relapsed\/refractory follicular lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2022;22:S391. https:\/\/doi.org\/10.1016\/S2152-2650(22)01563-4.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"577_CR54","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s41669-020-00204-z","volume":"4","author":"N Monga","year":"2020","unstructured":"Monga N, et al. Cost-effectiveness analyses, costs and resource use, and health-related quality of life in patients with follicular or marginal zone lymphoma: systematic reviews. PharmacoEconomics-Open. 2020;4:575\u201391.","journal-title":"PharmacoEconomics-Open"},{"issue":"4","key":"577_CR55","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40265-020-01446-1","volume":"81","author":"M Northend","year":"2021","unstructured":"Northend M, Townsend W. Novel therapy approaches to follicular lymphoma. Drugs. 2021;81(4):453\u201369. https:\/\/doi.org\/10.1007\/s40265-020-01446-1.","journal-title":"Drugs"},{"key":"577_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100992","volume":"57","author":"MJ Gordon","year":"2023","unstructured":"Gordon MJ, Smith MR, Nastoupil LJ. Follicular lymphoma: The long and winding road leading to your cure? Blood Rev. 2023;57: 100992. https:\/\/doi.org\/10.1016\/j.blre.2022.100992.","journal-title":"Blood Rev"},{"key":"577_CR57","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanubrutinib-relapsed-or-refractory-follicular-lymphoma. Accessed 29 Apr 2024."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00577-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00577-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00577-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T09:27:21Z","timestamp":1751275641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00577-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["577"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00577-z","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"25 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was funded by BeiGene USA, Inc. B.S. is employed by Moffitt Cancer Center; has received grants or contracts for investigator-initiated trials and preclinical work from Kite\/Gilead, Servier, and Jazz; has received consulting fees from Deciphera, Takeda, Kite\/Gilead, Novartis, BeiGene, Pfizer, Jazz, BMS, Amgen, Adaptive, Lilly, Autolus, and Syndax; has received payment or honoraria for educational events from Amgen, Adaptive, Kite\/Gilead, Lilly, Novartis, and Pfizer; has received support for attending meetings and\/or travel for presentations or advisory work from Kite and Amgen; is a member of the Data Safety Monitoring Board for Pepromene Bio; has served as a Steering Committee guest for Amgen; is Chair of the NCCN Acute Lymphoblastic Leukemia Guidelines; and provides unpaid clinical advice to BeiGene. M.X., E.K.S., and K.Y. are employed by BeiGene USA, Inc. W.F., J.K., P.Y.C., and M.D. are employed by Real Chemistry, which received funding for research support from BeiGene.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"B.S. is employed by Moffitt Cancer Center; has received grants or contracts for investigator-initiated trials and preclinical work from Kite\/Gilead, Servier, and Jazz; has received consulting fees from Deciphera, Takeda, Kite\/Gilead, Novartis, BeiGene, Pfizer, Jazz, BMS, Amgen, Adaptive, Lilly, Autolus, and Syndax; has received payment or honoraria for educational events from Amgen, Adaptive, Kite\/Gilead, Lilly, Novartis, and Pfizer; has received support for attending meetings and\/or travel for presentations or advisory work from Kite and Amgen; is a member of the Data Safety Monitoring Board for Pepromene Bio; has served as a Steering Committee guest for Amgen; is Chair of the NCCN Acute Lymphoblastic Leukemia Guidelines; and provides unpaid clinical advice to BeiGene. M.X., E.K.S., and K.Y. are employed by BeiGene USA, Inc. W.F., J.K., P.Y.C., and M.D. are employed by Real Chemistry, which received funding for research support from BeiGene.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data, material and\/or code availability"}},{"value":"Steering Committee member: B.S., E.K.S., J.K., and K.Y. Contribution to conception\/ design: M.X., W.F., E.K.S., and M.D. Acquisition of data: W.F., P.C., and M.D. Analysis of data: W.F., P.C., and M.D. Interpretation of data: B.S., M.X., W.F., and K.Y. Writing\u2014original draft: B.S., M.X., W.F., E.K.S., J.K., P.C., M.D., and K.Y. Writing\u2014review and editing: B.S., M.X., W.F., E.K.S., J.K., P.C., M.D., and K.Y.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}